Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Transforming the treatment
of severe autoimmune diseases

Imcyse is a clinical-stage biopharmaceutical company committed to advancing the development of a new class of specific immunotherapies. Focused on severe autoimmune diseases, the Company’s unique ImotopeTM platform has the potential to make a meaningful impact on a wide range of indications in the field of autoimmunity, as well as other diseases where immune system control breaks down.


Our technology platform produces synthetic peptides, that are based on naturally occurring proteins  - ImotopesTM - the next generation of targeted immunotherapeutics using the patient’s own immune system to break the abnormal immune responses thereby recalibrating the immune system.


The ImotopeTM platform has the potential to address a wide range of immunologic diseases. Our robust pipeline consists of two clinical and three pre-clinical programs, initially targeting Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Neuromyelitis Optica and Celiac Disease.

Business development

To drive the development and commercialization of our wide range of clinical and pre-clinical programs we are focused on advancing assets both in-house and through strategic partnerships.


March 01, 2023
Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes
April 13, 2022
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope™ IMCY-0141 for Multiple Sclerosis
March 14, 2022
Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference

©imcyse 2023